Analyst Price Target is $30.00
▲ +95.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Renalytix AI in the last 3 months. The average price target is $30.00, with a high forecast of $38.00 and a low forecast of $24.00. The average price target represents a 95.06% upside from the last price of $15.38.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Renalytix AI.
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.